Caribou Biosciences (CRBU) Interest & Investment Income (2020 - 2021)
Caribou Biosciences (CRBU) reported Interest & Investment Income of $76000.0 for Q4 2021, down 3.8% year-over-year from $79000.0 in Q4 2020, and up 245.45% on a QoQ basis from $22000.0 in Q3 2021.
Caribou Biosciences (CRBU) has 2 years of Interest & Investment Income data on file, last reported at $76000.0 in Q4 2021.
- Quarterly Interest & Investment Income fell 3.8% year-over-year to $76000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $223000.0 (changed N/A YoY) and the FY2021 annual result came in at $148000.0, down 37.29% from the prior year.
- Interest & Investment Income rose to $76000.0 in Q4 2021 per CRBU's latest filing, from $22000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $79000.0 in Q4 2020 and bottomed at $4000.0 in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 76,000.00 |
| Sep 30, 2021 | 22,000.00 |
| Jun 30, 2021 | 46,000.00 |
| Dec 31, 2020 | 79,000.00 |
| Sep 30, 2020 | 4,000.00 |
| Jun 30, 2020 | 11,000.00 |